CBD-THC Mixture Helped Brain Immune Cells Clear Alzheimer's Plaques in Mice | Research

The takeaway

A 99:1 CBD:THC botanical mixture enhanced microglial clearance of amyloid plaques in Alzheimer's mice, but also increased anxiety and depression-like behaviors.

Alzheimer's researchers, caregivers exploring cannabinoid research, and neuroscientists studying microglia.

Enhanced plaque clearance but increased anxiety/depression

What the researchers found

Chronic treatment (28 days) with CBD:THC (99:1) at 50 mg/kg twice daily in 5xFAD Alzheimer's mice enhanced microglial phagocytic activity and reduced amyloid peptide accumulation in neuritic plaques. However, the treatment also reduced locomotion, increased anxiety-like and depression-like behaviors, and had no effect on memory or motor coordination.

Why it matters

This is one of the first studies to show cannabinoids can enhance the brain's own plaque-clearing mechanisms in a living Alzheimer's model. However, the behavioral side effects present a clear challenge for translation to human treatment.

The numbers in context

50 mg/kg twice daily for 28 days. CBD:THC ratio 99:1. Enhanced microglial phagocytic activity by flow cytometry. Reduced amyloid accumulation by multiphoton microscopy. Increased anxiety and depression-like behaviors. No memory or motor coordination effects.

How the study worked

Male 5xFAD Alzheimer's mice treated with CBD:THC (99:1) 50 mg/kg subcutaneously twice daily for 28 days. Behavioral battery, protein expression analysis, flow cytometry for phagocytosis, and in vivo multiphoton microscopy for plaque imaging.

What this study cannot tell us

Only male mice studied. High subcutaneous dose (50 mg/kg BID) far exceeds typical human dosing. The 5xFAD model represents aggressive amyloid pathology, not all aspects of human Alzheimer's. 28-day treatment may be too short.

How to read the evidence

Well-designed preclinical study using advanced imaging (multiphoton microscopy), but only male mice and high doses limit translational relevance.

When this study was published

2026 study.

The bigger picture

The dual finding of enhanced plaque clearance alongside worsened behavior epitomizes the challenge of cannabinoid therapeutics in neurodegeneration. The immune benefits may be achievable at lower doses that avoid behavioral side effects, but this needs testing.

Questions still open

Could lower doses maintain the plaque-clearing benefits without the behavioral side effects? Would oral administration produce the same immune effects?

Common questions

Can CBD help clear Alzheimer's plaques?

In this mouse study, a CBD-dominant mixture enhanced the brain's immune cells (microglia) to better clear amyloid plaques. However, the same treatment worsened anxiety and depression behaviors.

Why is the CBD:THC ratio 99:1?

The formulation is CBD-dominant with a trace of THC. This reflects the growing interest in botanical mixtures that may have different effects than pure CBD or pure THC alone.

Read the original research

Treatment with a botanical mixture of cannabidiol:Δ9-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer's disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 194, 118902

View on PubMed ↗Publisher’s paper ↗

Citation

Ruiz de Martín Esteban, Samuel; Grande, M Teresa; Martínez-Relimpio, Ana M; Herráez-Aguilar, Diego; Mostany, Ricardo; Hillard, Cecilia J; Hind, William H; Romero, Julián. (2026). Treatment with a botanical mixture of cannabidiol:Δ9-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer's disease.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 194, 118902. https://doi.org/10.1016/j.biopha.2025.118902